Levetiracetam Ucb (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in modulating neurotransmitter release. This binding stabilizes synaptic transmission, lowers neuronal excitability, and diminishes the propagation of abnormal electrical discharges that generate seizures. The precise downstream pathways remain under investigation.

The appropriate dose of Levetiracetam Ucb is individualized by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage adjustments may be required for special populations such as those with impaired kidney function or the elderly. Patients should follow the prescriber’s instructions precisely.

Safety data for levetiracetam in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus. Limited information exists regarding excretion in breast milk; therefore, a risk‑benefit assessment should be performed before breastfeeding while on therapy.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Compared with older agents such as carbamazepine or phenytoin, levetiracetam offers a relatively favorable drug‑interaction profile and does not require routine therapeutic drug monitoring. It is generally well tolerated, though it may cause behavioral changes in some patients. Choice of therapy depends on seizure type, comorbidities, and individual response, and should be guided by a neurologist.

Levetiracetam tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures, which could affect tablet integrity.

Levetiracetam Ucb is supplied as oral tablets that are taken by mouth, usually with or without food. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing frequency is determined by the prescriber based on clinical response.

The most serious adverse reactions include severe allergic responses such as rash, angioedema, or anaphylaxis; psychiatric effects like depression, anxiety, or suicidal ideation; hematologic abnormalities such as neutropenia or thrombocytopenia; and rare but life‑threatening conditions like Stevens‑Johnson syndrome, toxic epidermal necrolysis, multiorgan failure, or pancreatitis. Immediate medical attention is required if any of these occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment who have not had dose adjustments, as well as for patients with a history of serious psychiatric disorders without close monitoring. Pregnant or breastfeeding women should only use it when clearly indicated after a thorough risk‑benefit evaluation.